News

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.

Anthropic's models may shorten research workflows, but neither company disclosed financial terms or productivity targets.

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

Novo Nordisk Shares Fall as Wall Street Questions Its Next Growth Move

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

Novo Nordisk dropped 'Nordisk' from its name, betting a culture reset can help it retake share from Eli Lilly.

The Danish drugmaker is shortening its name to Novo, but it will take more than a lean rebrand to win back Wall Street.

Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.

One date in the next decade is quietly doing all the work in Wall Street’s newest bear case.

Morgan Stanley sees Eli Lilly taking share before semaglutide's patents even become the bigger issue.

Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook

Morgan Stanley keeps Novo price target at 250 DKK

Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th

Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St

Germany is the first EU pill market, but pen-equivalent pricing means convenience--not discounting--must win adoption.

Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail...

Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker’s ability to return to growth and navigate an impending patent cliff.

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company’s growth trajectory. The stock fell more than 3% in Copenhagen trading Thursday.

Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their target price as midterm growth concerns and pipeline issues mount. The shares dropped 2.52% to DKK 297.25 as the broker adjusted its rating to 'sell', moving down from a previous 'hold' view...

By Tharuniyaa Lakshmi and Utkarsh Hathi Aug 25 (Reuters) - European shares rose on Tuesday as investors took comfort from a softer-than-feared U.S. sanctions package on Iran and falling oil prices,

The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by Novo Nordisk—from its U.S. biologics license application for apitegromab.

Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.

Wegovy pill upside has already played out, leaving the multiple at the European pharma average

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.

Novo raised its guidance, but pipeline impairments and slower product development kept investors focused on its competitive position.

Novo Nordisk (NYSE:NVO) raised its full-year guidance after reporting continued demand for its weight-loss treatments, but weaker-than-expected sales of its oral Wegovy medication and disappointing clinical trial results for a next-generation obesity therapy weighed heavily on investor sentiment. The company’s shares dropped 6% during US trading on Tuesday, while its Copenhagen-listed stock declined 4.

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated.